SARS-CoV-2 variants, spike mutations and immune escape

Cited by (1,002)

Items 801–900 of 1,002

1. XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
   Pehuén Pereyra Gerber, Maria J. Donde, Nicholas J. Matheson, Alexander I. Taylor · 2022 · Nature Communications
2. The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review
   Ranjan K. Mohapatra, Sarika Verma, Venkataramana Kandi, Ashish Kumar Sarangi, Véronique Seidel, Subrata Narayan Das, Ajit Behera, Hardeep Singh Tuli, Ashwani Kumar Sharma, Kuldeep Dhama · 2023 · ChemistrySelect
3. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir
   Shiho Torii, Kwang Su Kim, Jun Koseki, Rigel Suzuki, Shoya Iwanami, Yasuhisa Fujita, Yong Dam Jeong, Jumpei Ito, Hiroyuki Asakura, Mami Nagashima et al. · 2023 · PLoS Pathogens
4. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
   Vasileios Petrakis, Petros I. Rafailidis, Grigorios A. Trypsianis, Dimitrios Papazoglou, Periklis Panagopoulos · 2023 · Viruses
5. Strategies for the Management of Spike Protein-Related Pathology
   Matthew T. J. Halma, Christof Plothe, Paul Ellis Marik, Theresa Anne Lawrie · 2023 · Microorganisms
6. How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics?
   Jameel M. A. Abduljalil, Ahmed M. Elghareib, Ahmed Samir, Ahmed A. Ezat, Abdo A. Elfiky · 2023 · International Journal of Biological Macromolecules
7. Spreading processes with mutations over multilayer networks
   Mansi Sood, Anirudh Sridhar, Rashad Eletreby, Chai Wah Wu, Simon A. Levin, Osman Yağan, H. Vincent Poor · 2023 · Proceedings of the National Academy of Sciences
8. Umbelliferone and eriodictyol suppress the cellular entry of SARS-CoV-2
   Fang‐Ju Cheng, Chien‐Yi Ho, Tzong‐Shiun Li, Yeh Chen, Yi‐Lun Yeh, Ya-Ling Wei, Thanh Kieu Huynh, Bo‐Rong Chen, Hung-Yu Ko, Chen-Si Hsueh et al. · 2023 · Cell & Bioscience
9. Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis
   Zhu Liduzi Jiesisibieke, Wenyi Liu, Yupei Yang, Ching-Wen Chien, Tao‐Hsin Tung · 2023 · International Journal of Public Health
10. IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding
    Marcus J. Bolton, Jefferson José da Silva Santos, Claudia P. Arevalo, Trevor Griesman, Megan Watson, Shuk Hang Li, Paul F. Bates, Holly R. Ramage, Patrick C. Wilson, Scott E. Hensley · 2023 · Proceedings of the National Academy of Sciences
11. Computational screening combined with well-tempered metadynamics simulations identifies potential TMPRSS2 inhibitors
    Chelankara Suresh Sharanya, D. Sasikala Wilbee, Shijulal Nelson Sathi, Kathiresan Natarajan · 2024 · Scientific Reports
12. What do we know about the function of SARS-CoV-2 proteins?
    Santiago Justo Arévalo, Adriana Castillo Chávez, Carmen Sofia Uribe Calampa, Daniela Zapata Sifuentes, César J. Huallpa, Gianfranco Landa Bianchi, Romina Garavito-Salini Casas, Mauro Quiñones Aguilar, Roberto Pineda · 2023 · Frontiers in Immunology
13. The Evolving Faces of the SARS-CoV-2 Genome
    Maria Schmidt, Mamoona Arshad, Stephan H. Bernhart, Siras Hakobyan, Arsen Arakelyan, Henry Loeffler‐Wirth, Hans Binder · 2021 · Viruses
14. Development of a Multiplex Tandem PCR (MT-PCR) Assay for the Detection of Emerging SARS-CoV-2 Variants
    Richard Hale, Peter Crowley, Samir Dervisevic, Lindsay J. Coupland, Penelope R. Cliff, Saidat A R T Ebie, Luke B. Snell, Joel Paul, Cheryl Williams, Paul Anthony Randell et al. · 2021 · Viruses
15. A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features
    Saman Fatihi, Surabhi Rathore, Ankit Kumar Pathak, Deepanshi Gahlot, Mitali Mukerji, Nidhi Jatana, Lipi Thukral · 2021 · Current Research in Structural Biology
16. Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalized Patients During the First Year of the COVID-19 Pandemic
    Anna Marisa Cervantes-Arslanian, Chakradhar Venkata, Pria Anand, Joseph D. Burns, Charlene Jennifer Ong, Allison M. LeMahieu, Phillip J. Schulte, Tarun D. Singh, Alejandro A. Rabinstein, Neha Deo et al. · 2022 · Critical Care Explorations
17. Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL pro ) of SARS-CoV-2: molecular docking, ADME/T, molecular dynamic simulations, and DFT analysis
    Wahyu Eko Prasetyo, Heri Purnomo, Miracle Sadrini, Fajar Rakhman Wibowo, Maulidan Firdaus, Triana Kusumaningsih · 2022 · Journal of Biomolecular Structure and Dynamics
18. Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19
    Péter Buchwald · 2022 · Frontiers in Drug Discovery
19. A spatial vaccination strategy to reduce the risk of vaccine-resistant variants
    Xiyun Zhang, Gabriela Lobinska, Michal Feldman, Eddie Dekel, Martin A. Nowak, Yitzhak Pilpel, Yonatan Pauzner, Baruch Barzel, Ady Pauzner · 2022 · PLoS Computational Biology
20. Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands
    Alvin X. Han, Eva Kozanli, Jelle Koopsen, Harry Vennema, RIVM COVID-19 molecular epidemiology group, K. Hajji, Annelies Kroneman, Ivo Van Walle, Don Klinkenberg, Jacco Wallinga et al. · 2022 · eLife
21. Using multiple sampling strategies to estimate SARS-CoV-2 epidemiological parameters from genomic sequencing data
    Rhys P. D. Inward, Kris Varun Parag, Nuno R. Faria · 2022 · Nature Communications
22. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir)
    Ali Adel Dawood · 2022 · Advances in Medical Sciences
23. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
    Sapna Sharma, Thomas Vercruysse, Lorena Sánchez-Felipe, Winnie Kerstens, Madina Rasulova, Lindsey Bervoets, Carolien De Keyzer, Rana Abdelnabi, Caroline Shi-Yan Foo, Viktor Lemmens et al. · 2022 · Nature Communications
24. Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
    Hristo L. Svilenov, Romina Bester, Julia Sacherl, Ramona M. Absmeier, Carsten Peters, Ulrike Protzer, Carsten Brockmeyer, Johannes Büchner · 2022 · Communications Biology
25. Structural effects of spike protein D614G mutation in SARS-CoV-2
    Hisham Dokainish, Yuji Sugita · 2022 · Biophysical Journal
26. Rapid Evaluation of the Xpert® Xpress CoV-2 plus and Xpert® Xpress CoV-2/Flu/RSV plus Tests
    Lara Dominique Noble, Lesley Erica Scott, Riffat I. Munir, Mignon du Plessis, Kim Steegen, Lucia Hans, Puleng Marokane, Pedro Da Silva, Wendy Susan Stevens · 2022 · Diagnostics
27. Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes
    Martina Castellan, Gianpiero Zamperin, Giulia Franzoni, Greta Foiani, Maira Zorzan, Petra Drzewnioková, Marzia Mancin, Irene Brian, Alessio Bortolami, Matteo Pagliari et al. · 2023 · Viruses
28. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
    Abdul Aziz Al-Fattah Bin Yahaya, Kanwal Khalid, Hui Xuan Lim, Chit Laa Poh · 2023 · Viruses
29. Diagnostic, Prognostic and Mechanistic Biomarkers of COVID-19 Identified by Mass Spectrometric Metabolomics
    Mélanie Bourgin, Sylvère Durand, Guido Kroemer · 2023 · Metabolites
30. Highly Selective Aptamer‐Molecularly Imprinted Polymer Hybrids for Recognition of SARS‐CoV‐2 Spike Protein Variants
    Mark V. Sullivan, Francia Allabush, Harriet Flynn, Banushan Balansethupathy, Joseph A. Reed, Edward T. Barnes, Callum Robson, Phoebe O'Hara, Laura J. Milburn, David H. J. Bunka et al. · 2023 · Global Challenges
31. Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
    Takuya Tada, Ju-Yi Peng, Belinda M. Dcosta, Nathaniel Roy Landau · 2023 · JCI Insight
32. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico
    Marcela Peña Rodríguez, Jorge Hernández‐Bello, Natali Vega‐Magaña, Oliver Viera Segura, Mariel García‐Chagollán, Hazael Ramiro Ceja-Gálvez, Jesús Carlos Mora Mora, Francisco Israel Renteria-Flores, Octavio Patricio García-González, José Francisco Muñoz Valle · 2023 · Frontiers in Public Health
33. A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
    Prashant Dogra, Carmine Schiavone, Zhihui Wang, Javier Ruiz-Ramírez, Sergio Caserta, Daniela I. Staquicini, Christopher Markosian, Jin Wang, Dirk H. Sostman, Renata Pasqualini et al. · 2023 · JCI Insight
34. HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
    Ying Lu, Fan Shen, Wenqiang He, An‐Qi Li, Minghua Li, Xiaoli Feng, Yong‐Tang Zheng, Wei Ke Pang · 2023 · Acta Pharmaceutica Sinica B
35. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
    Pu-Ran Chen, P. Bergman, O. Blennow, L. Hansson, Stephan Mielke, P. Nowak, G. Söderdahl, A. Österborg, C. Edvard Smith, Jan Vesterbacka et al. · 2023 · EBioMedicine
36. Wastewater genomic sequencing for SARS-CoV-2 variants surveillance in wastewater-based epidemiology applications
    Xiaoqing Xu, Yu Deng, Jiahui Ding, Xiawan Zheng, Chunxiao Wang, Dou Wang, Lei Liu, Haogao Gu, Malik J. S. Peiris, Leo L. M. Poon et al. · 2023 · Water Research
37. A study on the effect of natural products against the transmission of B.1.1.529 Omicron
    Samar Sami Alkafaas, Abanoub Mosaad Abdallah, Aya Misbah Hussien, Heba Bedair, Mahmoud Abdo, Soumya Bikash Ghosh, Sara Samy Elkafas, Wilgince Apollon, Morteza Saki, Samah A. Loutfy et al. · 2023 · Virology Journal
38. The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
    Sara Piacentini, Anna Riccio, Silvia Santopolo, Silvia Pauciullo, Simone La Frazia, Antonio Rossi, Jean‐François Rossignol, M. Gabriella Santoro · 2023 · Frontiers in Microbiology
39. Mutational signature dynamics indicate SARS-CoV-2’s evolutionary capacity is driven by host antiviral molecules
    Kieran D. Lamb, Martha M. Luka, Megan Saathoff, Richard J Orton, My V. T. Phan, Matthew L. Cotten, Ke Yuan, David L. Robertson · 2024 · PLoS Computational Biology
40. The Wnt/β-catenin pathway is important for replication of SARS-CoV-2 and other pathogenic RNA viruses
    Zaikun Xu, Mohamed Elaish, Cheung Pang Wong, Bardes B. Hassan, Joaquín López-Orozco, Alberto Felix-Lopez, Natacha S. Ogando, Les P. Nagata, Lara K. Mahal, Anil Kumar et al. · 2024 · npj Viruses
41. Current Advances in Viral Nanoparticles for Biomedicine
    Xianxun Sun, Tao Tian, Yindong Lian, Zongqiang Cui · 2024 · ACS Nano
42. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo
    Kevin Chiem, Desarey Morales Vasquez, Jesus A. Silvas, Jun‐Gyu Park, Michael S. Piepenbrink, Julien Sourimant, Michelle J. Lin, Alexander L. Greninger, Richard Karl Plemper, Jordi Bertran Torrelles et al. · 2021 · Journal of Virology
43. Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
    Danique M.H. van Rijswijck, Albert Bondt, Max Hoek, Karlijn van der Straten, Tom G. Caniels, Meliawati Poniman, Dirk Eggink, Chantal B. E. M. Reusken, Godelieve J. de Bree, Rogier W. Sanders et al. · 2022 · Nature Communications
44. A phylogeny-based metric for estimating changes in transmissibility from recurrent mutations in SARS-CoV-2
    Damien Richard, Liam P. Shaw, Robert Lanfear, Russell B Corbett-Detig, Angie S. Hinrichs, Jakob McBroome, Yatish Turakhia, Mislav Acman, Christopher J. Owen, Cedric C.S. Tan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
45. Follow-up investigation and detailed mutational characterization of the SARS-CoV-2 Omicron variant lineages (BA.1, BA.2, BA.3 and BA.1.1)
    Qussai Abbas, Кусакин Алексей Викторович, Kinda Ali Sharrouf, Susan Jyakhwo, Aleksey S. Komissarov · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
46. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
    Stefan Glöckner, Franziska Hornung, Michael Baier, Sebastian Weis, Mathias Wilhelm Pletz, Stefanie Deinhardt‐Emmer, Bettina Löffler, the CoNAN Study Group · 2021 · Viruses
47. Genome-wide identification and prediction of SARS-CoV-2 mutations show an abundance of variants: Integrated study of bioinformatics and deep neural learning
    Md. Shahadat Hossain, A. Q. M. Sala Uddin Pathan, Md Nur Islam, Mahafujul Islam Quadery Tonmoy, Mahmudul Islam Rakib, Md. Adnan Munim, Otun Saha, Atqiya Fariha, Hasan Al Reza, Maitreyee Roy et al. · 2021 · Informatics in Medicine Unlocked
48. Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations
    Nguyễn Minh Tâm, Duc-Hung Pham, Đinh Minh Hiệp, Phuong‐Thao Tran, Dương Tuấn Quang, Sơn Tùng Ngô · 2021 · RSC Advances
49. First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy
    Valeria Micheli, Fiorenza Bracchitta, Alberto Rizzo, Alessandro Mancon, Davide Mileto, Alessandra Lombardi, Paola Stefanelli, Maria Rita Gismondo · 2021 · Clinical Infectious Diseases
50. The COVID-19 surge in Indonesia: what we learned and what to expect
    Eric Daniel Tenda, Moses Mazmur Asaf, Ariel Pradipta, Meutia Ayuputeri Kumaheri, Anindya Pradipta Susanto · 2021 · Breathe
51. Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection
    Lucie Sauerhering, Irina Kuznetsova, Alexandra Kupke, Lars Meier, Sandro Halwe, Cornelius Rohde, Jörg Schmidt, Rory Edward Morty, Olga Danov, Armin C. Braun et al. · 2022 · American Journal of Respiratory and Critical Care Medicine
52. A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern
    Ruyan Zhang, Xuguang Yin, Shihao Zhou, Hai-Wei Zhang, Jie Li Lu, Chen-Bin He, Jian Wang, Yu Wen, Yuting Li, Yanling Liu et al. · 2022 · Chemical Communications
53. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
    Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, Eliana F. Castro, Laura A. Bruno, William B. Stone, Paula S. Pérez, M. Laura Darriba, Lucia Beatriz Chemes, Julieta Alcaín et al. · 2022 · Frontiers in Immunology
54. Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity
    Wiebke Obermann, Alexandra Friedrich, Ramakanth Madhugiri, Paul Klemm, Jan Philipp Mengel, Torsten Hain, Stephan Pleschka, Hans‐Guido Wendel, Roland Karl Hartmann, Susanne Schiffmann et al. · 2022 · Viruses
55. Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
    Giuseppe Palladino, Cheng Wei Chang, Changkeun Lee, Nedzad Music, Ivna P. de Souza, Jonathan Nolasco, Samuel Amoah, Pirada Suphaphiphat, Gillis R. Otten, Ethan C. Settembre et al. · 2022 · Molecular Therapy — Methods & Clinical Development
56. Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program
    Joice do Prado Silva, Aline Brito de Lima, Luige Biciati Alvim, Frederico Scott Varella Malta, C P Mendonça, Paula Luize Camargos Fonseca, Filipe Romero Rebello Moreira, Daniel Costa Queiroz, Jorge Gomes Goulart Ferreira, Alessandro Clayton de Souza Ferreira et al. · 2022 · Viruses
57. Elucidating Design Principles for Engineering Cell‐Derived Vesicles to Inhibit SARS‐CoV‐2 Infection
    Taylor F. Gunnels, Devin M. Stranford, Roxana E. Mitrut, Neha P. Kamat, Joshua N. Leonard · 2022 · Small
58. FRET-Based haCE2 Receptor Mimic Peptide Conjugated Nanoprobe for Simple Detection of SARS-CoV-2
    Byunghoon Kang, Youngjin Lee, Jaewoo Lim, Dongeun Yong, Young Ki Choi, Sun Woo Yoon, Seungbeom Seo, Soojin Jang, Seong Uk Son, Taejoon Kang et al. · 2022 · Chemical Engineering Journal
59. Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using Nanopore Technology
    Anton Pembaur, Erwan Sallard, Patrick Philipp Weil, Jennifer Ortelt, Parviz Ahmad‐Nejad, Jan Postberg · 2021 · Microorganisms
60. In silico analysis of mutations near S1/S2 cleavage site in SARS‐CoV‐2 spike protein reveals increased propensity of glycosylation in Omicron strain
    Christopher A. Beaudoin, A. Pandurangan, So Yeon Kim, S. Hamaia, Christopher L-H Huang, T. Blundell, S. Vedithi, A. Jackson · 2022 · Journal of Medical Virology
61. COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning
    Anthony Huffman, Edison Ong, Junguk Hur, Adonis D’Mello, Hervé Tettelin, Yongqun Oliver He · 2022 · Briefings in Bioinformatics
62. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
    Manuel Rojas, Yhojan Rodríguez, Juan Carlos Hernández, Juan Camilo Díaz-Coronado, José Alejandro Daza Vergara, Verónica Posada Vélez, Jessica Porras Mancilla, Iván Araujo, Jairo Torres Yepes, Oscar Briceño Ricaurte et al. · 2022 · BMC Infectious Diseases
63. The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets
    Jianli Ma, Yuwei Deng, Minghui Zhang, Jinming Yu · 2022 · Virulence
64. Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study
    Min Hyung Kim, Yooju Nam, Nak‐Hoon Son, Namwoo Heo, Bongyoung Kim, Eawha Kang, Areum Shin, Andrew Jihoon Yang, Yoon Soo Park, Heejung Kim et al. · 2022 · Open Forum Infectious Diseases
65. (+)-Usnic acid and its salts, inhibitors of SARS‐CoV‐2, identified by using in silico methods and in vitro assay
    Eunseok Oh, Weihong Wang, Kyu-Hyung Park, Chanyoon Park, Youbin Cho, JunI Lee, Eunmo Kang, Heonjoong Kang · 2022 · Scientific Reports
66. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
    Abigael Eva Chaouat, Ilija Brizić, Paola Kučan Brlić, Nofar Atari, Limor Kliker, Or Alfi, Michal Mandelboim, Dana G. Wolf, Laith Tafish, Inbal Kol et al. · 2022 · iScience
67. Differential effect of SARS-CoV-2 infection on stress granule formation in Vero and Calu-3 cells
    Dongbum Kim, Sony Maharjan, Mijeong Kang, Jin-Soo Kim, Sangkyu Park, Minyoung Kim, Kyeongbin Baek, Suyeon Kim, Jun‐Gyo Suh, Younghee Lee et al. · 2022 · Frontiers in Microbiology
68. On the Origins of Omicron’s Unique Spike Gene Insertion
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Rohit Suratekar, Bharathwaj Raghunathan, Michiel J.M. Niesen, Venky Soundararajan · 2022 · Vaccines
69. When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy
    Emma Goulard Coderc de Lacam, Marharyta Blazhynska, Haochuan Chen, James C. Gumbart, Christophe J. Chipot · 2022 · Journal of Chemical Theory and Computation
70. Anti-SARS-CoV-2 and anticoagulant properties of Pentacta pygmaea fucosylated chondroitin sulfate depend on high molecular weight structures
    Rohini Dwivedi, Poonam Sharma, Friederike Eilts, Fuming Zhang, Robert J. Linhardt, Ritesh Tandon, Vitor Hugo Pomin · 2022 · Glycobiology
71. Biological effects of COVID-19 on lung cancer: Can we drive our decisions
    Beatrice Aramini, Valentina Masciale, Anna Valeria Samarelli, Roberto Tonelli, Stefania Cerri, Enrico Maria Clini, Franco Stella, Massimo Dominici · 2022 · Frontiers in Oncology
72. Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action
    Saroj Kumar Panda, Parth Sarthi Sen Gupta, Malay Kumar Rana · 2022 · Cell Biochemistry and Function
73. Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?
    Marco Leitzke · 2023 · Bioelectronic Medicine
74. Competition of SARS-CoV-2 variants on the pandemic transmission dynamics
    Jiaqi Chen, Changgui Gu, Zhongyuan Ruan, Ming Tang · 2023 · Chaos Solitons & Fractals
75. Co-incidence of BA.1 and BA.2 at the start of Singapore's Omicron wave revealed by Community and University Campus wastewater surveillance
    Feng Jun Desmond Chua, Se Yeon Kim, Eric Hill, Jia Wei Cai, Wei Lin Lee, Xiaoqiong Gu, Siti Aisyah Afri Affandi, Wee Chiew Kwok, W.J. Ng, Mats Leifels et al. · 2023 · The Science of The Total Environment
76. Molecular Analysis of SARS-CoV-2 Spike Protein-Induced Endothelial Cell Permeability and vWF Secretion
    Yuexi Guo, Venkateswarlu Kanamarlapudi · 2023 · International Journal of Molecular Sciences
77. Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain
    Noelia Trigo‐Tasende, Juan Andrés Vallejo, Soraya Rumbo‐Feal, Kelly Conde‐Pérez, Manuel Vaamonde, Ángel López‐Oriona, Inés Barbeito, Mohammed Nasser‐Ali, Rubén Reif, Bruno K. Rodiño‐Janeiro et al. · 2023 · Environmental Science and Pollution Research
78. Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2
    Dongxia Wang, Jakub Baudys, Sarah H. Osman, John Robert Barr · 2023 · Analytical and Bioanalytical Chemistry
79. Development of conserved multi-epitopes based hybrid vaccine against SARS-CoV-2 variants: an immunoinformatic approach
    Allah Rakha Yaseen, Muhammad Suleman, Abdul Salam Qadri, Asghar Ali, Iram Arshad, Daulat Munaza Khan · 2023 · In Silico Pharmacology
80. An overview for monitoring and prediction of pathogenic microorganisms in the atmosphere
    Jianping Huang, Danfeng Wang, Yong‐Guan Zhu, Zifeng Yang, Maosheng Yao, Xiaoming Shi, Taicheng An, Qiang Zhang, Cunrui Huang, Xinhui Bi et al. · 2023 · Fundamental Research
81. ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
    Tao Ni, Luiza Mendonça, Yanan Zhu, Andrew Howe, Julika Radecke, Pranav N. M. Shah, Yuewen Sheng, Anna-Sophia Krebs, Helen M. E. Duyvesteyn, Elizabeth R. Allen et al. · 2023 · iScience
82. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
    L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
83. Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
    Yuan‐Qin Min, Wei Xiong, Wei Shen, Xingyu Liu, Qianqian Qi, Yuanyuan Zhang, Ruochen Fan, Fang Fu, Heng Xue, Hang Yang et al. · 2024 · Science Advances
84. Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages
    H. J. Yang, Xuemei He, Shi H, Cai He, Lei Hong, Heng He, Li Yang, Wei Wang, Guobo Shen, Jinliang Yang et al. · 2025 · Signal Transduction and Targeted Therapy
85. Probing the formation, structure and free energy relationships of M protein dimers of SARS-CoV-2
    Yi-Peng Cao, Rui-Rui Yang, Wei Wang, Sheng Jiang, Chengwen Yang, Ning-Bo Liu, Hong-Ji Dai, Imshik Lee, Xiang-Fei Meng, Zhiyong Yuan · 2022 · Computational and Structural Biotechnology Journal
86. High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity
    Georg Bauer · 2022 · Exploration of Immunology
87. Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
    Wan Yang, Sharon K. Greene, Eric R. Peterson, Wenhui Li, Robert W. Mathes, Laura E. Graf, Ramona Lall, Scott Hughes, Jade Wang, Annie D. Fine · 2022 · Science Advances
88. Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2
    Yifan Lin, Xuejiao Liao, Xuezhi Cao, Zhaoyong Zhang, Xiuye Wang, Xiaomeng He, Huiping Liao, Bin Ju, Furong Qi, Hairong Xu et al. · 2025 · Journal of Clinical Investigation
89. Receptor binding domain‐IgG levels correlate with protection in residents facing SARS‐CoV‐2 B.1.1.7 outbreaks
    Hubert Blain, Édouard Tuaillon, Lucie Gamon, Amandine Pisoni, Stéphanie Miot, Valentin Delpui, Nejm Si-Mohamed, Clémence Niel, Yves Rolland, Brigitte Montès et al. · 2021 · Allergy
90. Elucidating important structural features for the binding affinity of spike ‐ SARS‐CoV ‐2 neutralizing antibody complexes
    Divya Sharma, Puneet Rawat, Janakiraman Vani, M. Michael Gromiha · 2021 · Proteins Structure Function and Bioinformatics
91. Colloidal stability of polymer coated zwitterionic Au nanoparticles in biological media
    Daniel Valdepérez, Nicole Wutke, Lisa‐Maria Ackermann, Wolfgang Johann Parak, Markus Klapper, Beatriz Pelaz · 2022 · Inorganica Chimica Acta
92. Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies
    Du Guo, Huaichuan Duan, Yan Cheng, Yueteng Wang, Jianping Hu, Hubing Shi · 2022 · Molecular Biomedicine
93. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters
    Kyle Lee O’Donnell, Chad S. Clancy, Amanda J. Griffin, Kyle Shifflett, Tylisha Gourdine, Tina Thomas, Carrie Mae Long, Wakako Furuyama, Andrea Marzi · 2022 · Frontiers in Immunology
94. Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection
    Vaibhav Upadhyay, Casey Patrick, Alexandra Lucas, Krishna M.G. Mallela · 2022 · Biochemistry
95. An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2
    İsmail Çeli̇k, Magda H. Abdellattif, Trina Ekawati Tallei · 2022 · Biology
96. Characterization of the Cross-Species Transmission Potential for Porcine Deltacoronaviruses Expressing Sparrow Coronavirus Spike Protein in Commercial Poultry
    Moyasar A. Alhamo, Patricia A. Boley, Mingde Liu, Xiaoyu Niu, Kush Kumar Yadav, Carolyn M. Lee, Linda J. Saif, Qiuhong Wang, Scott P. Kenney · 2022 · Viruses
97. Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
    David J. H. Bian, Siham Sabri, Bassam Abdulkarim · 2022 · Cancers
98. Tracing the origin of Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2): A systematic review and narrative synthesis
    Nagendra N. Thakur, Sayak Das, Swatantra Kumar, Vimal K. Maurya, Kuldeep Dhama, Janusz Tadeusz Paweska, Ahmed Sayed Abdel-Moneim, Amita Jain, Anil Kumar Tripathi, Bipin Puri et al. · 2022 · Journal of Medical Virology
99. Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
    Ana C. Puhl, Giovanni Freitas Gomes, Samara Damasceno, Ethan J. Fritch, James A. Levi, Nicole J. Johnson, Frank Scholle, Lakshmanane Premkumar, Brett L. Hurst, Felipe Lee-Montiel et al. · 2022 · ACS Omega
100. Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors
     Marcel Walser, Jennifer Mayor, Sylvia Rothenberger · 2022 · Viruses